Alkermes plc may be best known for its drugs that treat addiction and schizophrenia—and for a 2011 trans-Atlantic deal in which it bought an Irish drug maker, doubled in size, and moved from Waltham to Dublin.
But the biotechnology company got a new lift Wednesday, saying the Food and Drug Administration had granted fast-track status for its experimental medicine to combat depression, intended for patients who don’t respond to standard therapies.
The news, coming after Alkermes said it would launch a pivotal late-stage trial of the drug early next year, signaled the FDA’s interest in new medicines for major depressive disorders. About 11 million patients each year start taking drugs to treat depression-- most of them seeking to boost serotonin levels—but roughly 60 percent of them don’t respond to the medications. Full story for BostonGlobe.com subscribers.